Rangering i aksjer
#39206
hVIVO plc (HVO) operates as a premier full-service Contract Research... hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
Antall utestående aksjer for HVIVO plc (HVO)
Antall utestående aksjer per August 2026: 0
Ifølge HVIVO plc sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av August 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for HVIVO plc (HVO) fra 2026 til 2026
Utestående aksjer ved utgangen av hvert år
| År |
Utestående aksjer |
Endre |
|
Ikke nok data for de angitte datoene. |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap |
Utestående aksjer |
Forskjell |
Land |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
0.00 |
-
|
BE
|
